Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing

Abstract

BACKGROUND: The World Health Organization recommends drug-susceptibility testing of Mycobacterium tuberculosis complex for all patients with tuberculosis to guide treatment decisions and improve outcomes. Whether DNA sequencing can be used to accurately predict profiles of susceptibility to first-line antituberculosis drugs has not been clear. METHODS: We obtained whole-genome sequences and associated phenotypes of resistance or susceptibility to the first-line antituberculosis drugs isoniazid, rifampin, ethambutol, and pyrazinamide for isolates from 16 countries across six continents. For each isolate, mutations associated with drug resistance and drug susceptibility were identified across nine genes, and individual phenotypes were predicted unless mutations of unknown association were also present. To identify how whole-genome sequencing might direct first-line drug therapy, complete susceptibility profiles were predicted. These profiles were predicted to be susceptible to all four drugs (i.e., pansusceptible) if they were predicted to be susceptible to isoniazid and to the other drugs or if they contained mutations of unknown association in genes that affect susceptibility to the other drugs. We simulated the way in which the negative predictive value changed with the prevalence of drug resistance. RESULTS: A total of 10,209 isolates were analyzed. The largest proportion of phenotypes was predicted for rifampin (9660 [95.4%] of 10,130) and the smallest was predicted for ethambutol (8794 [89.8%] of 9794). Resistance to isoniazid, rifampin, ethambutol, and pyrazinamide was correctly predicted with 97.1%, 97.5%, 94.6%, and 91.3% sensitivity, respectively, and susceptibility to these drugs was correctly predicted with 99.0%, 98.8%, 93.6%, and 96.8% specificity. Of the 7516 isolates with complete phenotypic drug-susceptibility profiles, 5865 (78.0%) had complete genotypic predictions, among which 5250 profiles (89.5%) were correctly predicted. Among the 4037 phenotypic profiles that were predicted to be pansusceptible, 3952 (97.9%) were correctly predicted. CONCLUSIONS: Genotypic predictions of the susceptibility of M. tuberculosis to first-line drugs were found to be correlated with phenotypic susceptibility to these drugs. (Funded by the Bill and Melinda Gates Foundation and others.).

Shown for reading. Its publisher allows quoting it, not republishing it.

References 25

1. 1.

   World Health Organization. Global Tuberculosis Report 2017. 2017;:1–262.

   Not in our library

2. 2.

   Shah NS, Auld SC, Brust JCM, et al. Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. N Engl J Med 2017;376(3):243–53.

   Not in our library10.1056/nejmoa1604544

3. 3.

   Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377(9776):1495–505.

   Not in our library10.1016/s0140-6736(11)60438-8

4. 4.

   Sanchez-Padilla E, Merker M, Beckert P, et al. Detection of Drug-Resistant Tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med 2015;372(12):1181–2.

   Not in our library10.1056/nejmc1413930

5. 5.
   Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study · 2016

   No notice
6. 6.
   Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study · 2015

   Corrected
7. 7.

   World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. 2014:1–98.

   Not in our library

8. 8.

   The 100,000 Genomes Project Protocol v3, Genomics England. doi:10.6084/m9.figshare.4530893.v2. 2017.

   Not in our library

9. 9.

   Gerton Lunter MG. Stampy: A statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Research 2011;21(6):936–9.

   Not in our library10.1101/gr.111120.110

10. 10.

    Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25(16):2078–9.

    Not in our library10.1093/bioinformatics/btp352

11. 11.

    Iqbal Z, Caccamo M, Turner I, Flicek P, McVean G. De novo assembly and genotyping of variants using colored de Bruijn graphs. Nat Genet 2012;44(2):226–32.

    Not in our library10.1038/ng.1028

12. 12.
    A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis · 2017

    No notice
13. 13.

    Yadon AN, Maharaj K, Adamson JH, et al. A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. Nat Comms 2017:1–10.

    Not in our library10.1038/s41467-017-00721-2

14. 14.

    Casali N, Nikolayevskyy V, Balabanova Y, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 2014;46(3):279–86.

    Not in our library10.1038/ng.2878

15. 15.

    Manson AL, Cohen KA, Abeel T, et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat Genet 2017;49(3):395–402.

    Not in our library10.1038/ng.3767

16. 16.

    Schön T, Miotto P, Köser CU, Viveiros M, Boettger E, Cambau E. Mycobacterium tuberculosis drug resistance testing: challenges, recent developments and perspectives. Clinical Microbiology and Infection 2016:1–33.

    Not in our library10.1016/j.cmi.2016.10.022

17. 17.

    Nikolayevskyy V, Hillemann D, Richter E, et al. External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study. PLoS ONE 2016;11(4):e0152926–14.

    Not in our library10.1371/journal.pone.0152926

18. 18.

    Rigouts L, Gumusboga M, de Rijk WB, et al. Rifampin Resistance Missed in Automated Liquid Culture System for Mycobacterium tuberculosis Isolates with Specific rpoB Mutations. Journal of Clinical Microbiology 2013;51(8):2641–5.

    Not in our library10.1128/jcm.02741-12

19. 19.

    André E, Goeminne L, Colmant A, Beckert P, Niemann S, Delmee M. Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance- conferring mutation undetected by commercial assays. Clinical Microbiology and Infection 2017;23(4):267.e5–267.e7.

    Not in our library10.1016/j.cmi.2016.12.009

20. 20.

    Sreevatsan S, Stockbauer KE, Pan X et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 1997;41(8):1677.

    Not in our library10.1128/aac.41.8.1677

21. 21.
    <named-content content-type="genus-species">Mycobacterium tuberculosis</named-content> Pyrazinamide Resistance Determinants: a Multicenter Study · 2014

    Not checked
22. 22.

    Coronel J, Roper M, Mitchell S, et al. MODS accreditation process for regional reference laboratories in Peru: validation by GenoType® MTBDRplus. Int J Tuberc Lung Dis 2010;14(11):1475–80.

    Not in our library

23. 23.
    Same-Day Diagnostic and Surveillance Data for Tuberculosis via Whole-Genome Sequencing of Direct Respiratory Samples · 2017

    No notice
24. 24.

    Heyckendorf J, Andres S, Köser CU, et al. What is resistance? Impact of phenotypic versus molecular drug resistance testing on multi- and extensively drug-resistant tuberculosis therapy. Antimicrob Agents Chemother 2017:AAC.01550–17–37.

    Not in our library10.1128/aac.01550-17

25. 25.

    Ben J Marais, Walker TM, Cirillo DM, et al. Comment: Aiming for zero tuberculosis transmission in low-burden countries. The Lancet Respiratory 2017:1–2.

    Not in our library10.1016/s2213-2600(17)30382-x

Cited by papers we hold 10

• Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance · 2022
  Not checked
• Next Generation and Other Sequencing Technologies in Diagnostic Microbiology and Infectious Diseases · 2022
  No notice
• A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics · 2022
  No notice
• The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis · 2022
  No notice
• Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs · 2021
  Not checked
• Whole-genome sequencing of Mycobacterium tuberculosis directly from clinical samples for high-resolution genomic epidemiology and drug resistance surveillance: an observational study · 2020
  Not checked
• Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges · 2019
  No notice
• Antibiotic resistance prediction for Mycobacterium tuberculosis from genome sequence data with Mykrobe · 2019
  No notice
• Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs · 2019
  No notice
• Using Genomics to Track Global Antimicrobial Resistance · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.